The performance of a direct sandwich enzyme-linked immunosorbent assay (ELISA) for detecting Aspergillus galactomannan was compared with that of the Pastorex Aspergillus antigen latex agglutination (LA) test by using 532 serum samples from 61 patients at risk for invasive aspergillosis. The ELISA gave positive results earlier in the course of infection than did the LA test. A sensitivity of 70% and a specificity of 86% were obtained for the LA test and corresponding values of 90 and 84% were obtained for the ELISA when a series of serum samples was employed.
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Aspergillus fumigatus is a ubiquitous fungus capable of causing life-threatening opportunistic infections in immunocompromised patients (3) . Inhalation of airborne Aspergillus conidia and germination of spores in the alveoli primarily result in pulmonary infection, although dissemination to other organs may occur. The successful diagnosis of invasive aspergillosis (IA) is frustrated by the difficulty in obtaining specimens which demonstrate the organism directly. Serologic techniques have been used in an attempt to establish diagnosis in early stages of infection but have proven to be unsuccessful for immunocompromised patients because of the patients' impaired ability to produce humoral responses. The detection of circulating Aspergillus antigens in body fluids, e.g., in serum and urine, is promising, but despite the development of several methods for such detection (1, 8) , none has gained widespread acceptance. Recently, a direct double sandwich enzyme-linked immunosorbent assay (ELISA) has been developed; this assay employs the rat monoclonal antibody EB-A2 to detect galactomannan (GM), a cell wall component of Aspergillus spp. (15, 16) . The EB-A2 antibody is also used in the commercially available Pastorex Aspergillus latex agglutination (LA) test (Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France) (16), but the detection limit can be lowered 10-fold by employing the antibody as a captor and a detector (15) , which may allow IA to be diagnosed earlier. We investigated this possibility by testing the ELISA with a series of 532 serum samples which had been previously analyzed by LA (18) to attempt to diagnose IA in 61 immunocompromised patients at high risk for the disease.
A total of 532 serum samples from 61 patients were collected during chemotherapy-induced neutropenia and were stored at Ϫ80ЊC. At least two serum samples were available from each patient. Before testing, all serum samples were treated as described previously for Candida mannan (13) to dissociate immune complexes. All LA tests were performed by the same technician exactly as described by the manufacturer. For the ELISA, the supernatants of the serum samples were obtained by centrifuging the samples at 15,000 ϫ g for 10 min. The ELISA was performed as described previously (15) . Briefly, 50 l of the treated sample and 50 l of horseradish peroxidaseconjugated EB-A2 were placed in the wells of a microtiter plate coated with monoclonal antibody EB-A2, and the plates were incubated at 37ЊC for 90 min. After the plates were washed, 100 l of buffer containing ortho-phenylenediamine dihydrochloride was added to the wells, and the plates were incubated for 30 min. The reaction was stopped with 50 l of 4 M sulfuric acid, and the optical density was read at 492 nm. The optical density of antigen-negative serum spiked with 1 ng of GM per ml provided the cutoff value (15) , and a positive and a negative control were included with each test.
The results for the 532 serum samples tested by LA and ELISA are shown in Table 1 . A total of 325 serum samples were obtained from 33 patients who had a low likelihood of IA, i.e., patients for whom there was no clinical, microbiological, histological, or radiological evidence of infection. Three samples were positive in both tests, 2 samples (1.5%) were positive in the LA test alone, and 22 samples (7.7%) were positive only in the ELISA. There was clinical evidence of IA in the other 28 patients, who had all developed pulmonary infiltrates and had been febrile (temperatures of Ͼ38ЊC) for 3 days despite broadspectrum antimicrobial therapy. For 18 of these patients, the courses of infection and the results of cultures suggested that IA was unlikely. With the 120 serum samples from these 18 patients, positive results were obtained for 3 samples (2.5%) in both tests and 10 samples (8.3%) were positive by ELISA ( Table 1 ). The clinical characteristics of the remaining 10 patients with possible IA (patients showing clinical and radiological evidence for IA but having negative culture results) or proven IA (patients showing histopathological evidence of tissue invasion at autopsy and having positive Aspergillus culture results) are shown in Table 2 , together with the results of the analyses of 87 serum samples from these patients. GM was not detected by either test in any of the serum from patient 1, who had a proven infection. Very low levels of GM in serum, due to limited fungal invasion of the pulmonary blood vessels or the release of low levels of GM by the fungus into the body fluids, may have contributed to the false-negative result for this patient. For the entire patient population, the sensitivity and specificity of the LA test were 70 and 86%, respectively, and the sensitivity and specificity of the ELISA were 90 and 71%, respectively. When a true-positive result for the ELISA was defined as two consecutive positive serum samples, the sensitivity was similar (90%) but the specificity increased to 84%.
Diagnosing IA at an early stage of infection is difficult. The culture of Aspergillus spp. from the sputa or bronchoalveolar lavage fluids of patients at high risk for IA is highly indicative of infection, but the diagnostic reliability of culture is low (11) . Therefore, more-sensitive methods, such as PCR (10, 12, 14, 17) and Aspergillus antigen detection (2, 4-9, 15, 18, 19) , are under investigation. The detection of GM by the Pastorex Aspergillus LA test has been evaluated at several institutes (2, 4-7, 9, 18, 19) , and the test showed sensitivities of up to 95% with serum samples from patients with a high index of suspicion for IA (4, 5) . The LA test was also found to yield positive results earlier than conventional tests for 68% of patients with proven IA (5). However, these observations were not confirmed by others (2, 6, 7, 9, 18, 19) , and a sensitivity of only 38% has been reported (9). In our study, the LA test yielded positive results only during advanced stages of infection in most patients with suspected IA and did not contribute to an earlier diagnosis (18) . The present study showed that the ELISA detected GM in serum up to 5 days earlier than the LA test did. Although both LA and ELISA failed to detect one proven infection, the ELISA detected GM in two additional patients for whom the LA test continued to yield negative results. Moreover, GM was detected in more serum samples by ELISA than by LA. This suggests that monitoring sequential serum samples from high-risk patients during neutropenia may allow the diagnosis of IA to be made at an earlier stage of infection.
The increased sensitivity of the ELISA, however, was associated with an increase in false-positive results. A rate of 8% false positives by ELISA has been found by others (15) . There- d Values are numbers of days elapsed between the first day of fever (temperature of Ͼ38.5ЊC) and a positive result by either test. Patient 9 developed severe graft-versus-host disease (III) and was treated with high doses of corticosteroids. With patient 10, a fever of unknown origin was present for 3 months, but 3 days before the first serum sample was obtained, respiratory failure developed and infiltrates were demonstrated by chest roentgenogram.
fore, in order to identify a genuine elevation of the GM level in serum, positive ELISA results should be found for at least two consecutive serum samples.
Our results suggest that antigen detection at regular intervals by the double sandwich ELISA may allow the early diagnosis of IA in immunocompromised patients. Twice-weekly collection and testing of serum samples from a patient during the period of neutropenia should be sufficient to detect an increase in the GM level in serum early in the course of infection. In the case of a positive ELISA result, the collection and testing of serum samples should be continued in order to exclude the possibility of a false-positive result. Furthermore, confirmation of suspected IA should be obtained by chest roentgenogram, computer tomography, or bronchoalveolar lavage. Prospective studies following these guidelines are needed to establish the clinical value of this new ELISA.
